Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AK5G
|
|||
| Former ID |
DIB003241
|
|||
| Drug Name |
RPAF-AH
|
|||
| Indication | Sepsis [ICD-11: 1G40-1G41; ICD-9: 995.91] | Discontinued in Phase 3 | [1] | |
| Company |
ICOS Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Platelet-activating factor acetylhydrolase (PLA2G7) | Target Info | Modulator | [2] |
| KEGG Pathway | Ether lipid metabolism | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Pathway Interaction Database | Lissencephaly gene (LIS1) in neuronal migration and development | |||
| WikiPathways | IL1 and megakaryotyces in obesity | |||
| Synthesis, Secretion, and Deacylation of Ghrelin | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00037687) Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006777) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.